Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors

Phase 2 Terminated 9 enrolled Memorial Sloan Kettering Cancer Center

Non-randomizedParallel-groupOpen-labelTreatment

This study is being done to learn whether a new method to prevent rejection between the donor immune system and the patient's body is effective.

Evaluation	Drug	Modality	Dose	Route
Subject	Busulfan	Small molecule	—	—
Subject	Clofarabine	Other / unclassified	20 mg/m2	Intravenous
Subject	Clofarabine	Other / unclassified	30 mg/m2	Intravenous
Subject	Cyclophosphamide	Other / unclassified	60 mg/kg	Intravenous
Subject	Fludarabine	Small molecule	25 mg/m2	Intravenous
Subject	Melphalan	Small molecule	70 mg/m2	Intravenous
Subject	Thiotepa	Other / unclassified	5 mg/kg	Intravenous
Background	Rituximab	Monoclonal antibody	200 mg	Intravenous